KR102321574B1 - Customized cerebral cardiovascular disease management system and method based on apo e gene information analysis - Google Patents

Abstract

The present invention relates to a cerebrovascular and cardiovascular disease management system based on APOE genetic information analysis. The system comprises: a communications server that receives a user's personal health record information and the user's genetic information derived from a genetic test result; a gene server that stores information on genotype information correlated with cerebrovascular and cardiovascular disease; a service providing server that provides a customized cerebrovascular and cardiovascular disease management service including lifestyle and dietary management based on the user's personal health record information, the user's genetic information, and the genotype information correlated with cerebrovascular and cardiovascular disease; and a user terminal that conveys the user's request for the customized cerebrovascular and cardiovascular disease management service to the service providing server, and displays the customized cerebrovascular and cardiovascular disease management service provided by the service providing server so that the user can check the service. In accordance with the present invention, it is possible to depart from existing uniform management not reflecting genetic characteristics by analyzing personal characteristics of cerebrovascular and cardiovascular disease based on APOE genotypes and health record data through individual genetic information analysis and systematically managing the cerebrovascular and cardiovascular disease, thereby managing the cerebrovascular and cardiovascular disease more effectively.

Description

Apo E (Apo E) gene information analysis-based customized cerebrovascular disease management system and method {CUSTOMIZED CEREBRAL CARDIOVASCULAR DISEASE MANAGEMENT SYSTEM AND METHOD BASED ON APO E GENE INFORMATION ANALYSIS}

The present invention relates to a customized cerebrovascular disease management system based on Apo E gene information analysis, and more particularly, according to the user's gene type based on the characteristics of cerebrovascular disease by Apo E gene type. It relates to a system that effectively manages cerebrovascular disease.

Cerebrovascular disease is a disease caused by abnormalities in the blood vessels of the brain and cardiovascular system, and occurs in the arteries surrounding the brain and heart. Examples of cerebrovascular diseases include stroke, cerebral infarction, cerebral thrombosis, transient ischemic attack, cerebral aneurysm rupture, and the like.

Apo E is a major cholesterol carrier in the brain, and it is known that the incidence of cerebrovascular disease increases in people with the Apo E 4 allele based on epidemiological studies of various ethnic groups.

Cerebrovascular disease is known to act as a risk factor for dementia independently of Apo E gene mutation and other vascular risk factors. Other vascular risk factors include hypertension, hyperlipidemia, diabetes, smoking and cardiovascular disease, and it is known that the presence of one or more Apo E4 alleles increases the risk for Cerebro-Vascular Disease.

The Apo E gene has a genetic polymorphism due to a combination of alleles, and is strongly associated with the risk of cardiovascular disease and Alzheimer's disease. 65-80% of all Alzheimer's patients are associated with at least one Apo E4, and Apo E4 is associated with Alzheimer's by 4-fold (one allele) to 14-fold (two alleles) compared to Apo E3/3 homogeneity ( allele)) is known to increase. Apo E2 increases apogenic lipoprotein levels, and Apo E4 increases LDL levels, which is known to increase the risk for cardiovascular disease. Apo E4 increases the risk of plasma low-density lipoprotein (LDL) and atherosclerosis, and is reported as an index that can predict the incidence of coronary artery disease or cerebrovascular disease accompanied by atherosclerosis.

Defective receptor binding in Apo E2 can lead to hyperlipidemia and increased risk of atherosclerosis in the context of other genetic or environmental factors. Plasma-accumulating β-very-low-density lipoprotein (β-VLDL) induces cholesterol accumulation in peripheral arteries, increasing the risk of atherosclerosis. In addition, the expression of Apo E and lipoprotein lipase was observed at the site of atherosclerotic lesions, suggesting the possibility of a direct role in atherosclerosis.

The frequency of the Apo E4 allele was higher in the coronary artery disease group than in the normal control group, and in particular, the myocardial infarction patient tended to be significantly higher than the normal control group. The association between the Apo E allele and coronary artery disease has been reported by numerous studies suggesting that the Apo E4 allele is strongly associated with an increase in the prevalence and mortality of coronary artery disease. In Apo E3/4, myocardial infarction occurs more frequently at a young age, and in patients with coronary artery disease under 40 years of age who have had coronary angiography, the frequency of Apo E4/4 is 16 times higher, and in Apo E4/4 restenosis after coronary angioplasty. It has been reported that many In addition, it was found that environmental risk factors such as smoking and diet interact as factors that increase the risk of Apo E.

In recent years, medical technology and information technology have developed, and the importance of health management has been greatly emphasized in the age of aging and well-being. Various types of health management systems are being developed that enable real-time monitoring and management of diseases by medical institutions or doctors. However, most of the existing disease management was uniform management based on disease diagnosis that did not reflect genetic characteristics. However, recently, research on the identification of a gene type (genotype) correlated with the incidence rate of a specific disease through genomic research and diagnosis or treatment of a disease based on these genetic characteristics is being actively conducted.

The present invention systematically manages cerebrovascular disease based on individual cerebrovascular disease characteristics analysis based on the Apo E gene type and health record data through individual genetic information analysis, thereby providing uniform management that does not reflect existing genetic characteristics. The purpose of this study is to more effectively manage cerebrovascular disease.

In order to achieve the above object, the present invention provides a communication server for receiving the user's personal health record information and the user's genetic information derived from the genetic test result; A gene server that stores information on a gene type (Genotype) correlated with cerebrovascular disease; Based on the user's personal health record information, the user's genetic information derived from the genetic test result, and the genotype information correlated with cerebrovascular disease, a customized cerebrovascular disease management service including lifestyle and dietary management is provided. a service providing server to provide;

Genetic information analysis-based customization including a user terminal that transmits a request for a user to provide a customized cerebrovascular disease management service to the service providing server or displays a customized cerebrovascular disease management service provided by the service providing server so that the user can check it It is an aspect of the present invention to provide a cerebrovascular disease management system.

In addition, in order to achieve the above object, the present invention includes the steps of: (a) obtaining the user's personal health record information and the user's genetic information derived from the genetic test result; (b) matching the user's genetic information derived from the genetic test result and the gene type information correlated with cerebrovascular disease; (c) customized cerebrovascular disease management service including lifestyle and diet management in consideration of the user's genetic specificity using the user's personal health record information and the matched gene type information correlated with the cerebrovascular disease It is another aspect of the present invention to provide a customized cerebrovascular disease management method based on genetic information analysis comprising the step of providing.

According to the present invention as described above, by systematically managing cerebrovascular disease by analyzing individual cerebrovascular disease characteristics based on the Apo E gene type and health record data through individual genetic information analysis, the existing genetic characteristics are not reflected. It is effective in managing cerebrovascular disease more efficiently by breaking away from the non-uniform management.

1 shows the configuration of a customized cerebrovascular disease management system based on Apo E gene information analysis according to an embodiment of the present invention.
2 is a diagram illustrating the configuration of a service providing server of a customized cerebrovascular disease management system based on Apo E gene information analysis according to an embodiment of the present invention.

Hereinafter, embodiments of the present invention will be described in detail with reference to the accompanying drawings.

Referring to FIG. 1 , a customized cerebrovascular disease management system 100 based on genetic information analysis according to an embodiment of the present invention includes a communication server 110 , a gene server 120 , a service providing server 130 , and a user terminal ( 140).

The communication server 110 may receive the user's personal health record information and the user's genetic information derived from the genetic test result.

The personal health record information of the user received by the communication server 110 preferably includes information on current diseases including information on blood lipid levels, diabetes, high blood pressure, and obesity, but is not limited thereto. In addition, body information such as the user's weight and height may be included. In the case of body information such as a user's weight and height, it may be directly transmitted from the user terminal 140 in addition to checking from the personal health record information.

The user's genetic information received by the communication server 110 is a genetic test result of a genetic analysis specialized institution, and preferably includes cardiovascular-related genes, cerebrovascular-related genes, diabetes-related genes, metabolic disease-related genetic test results, and the like. However, the present invention is not limited thereto.

The gene server 120 may store genotype information correlated with cerebrovascular disease. The gene type information correlated with cerebrovascular disease stored in the gene server 120 may be apo E genotype information. The apo E genotype preferably includes at least one of apo E2 (Apo E2), apo E3 (Apo E3), and apo E4 (Apo E4).

In the case of apo E2 (Apo E2) and apo E4 (Apo E4) genotypes, which have at least one single disease among risk factors for cerebrovascular disease (abnormal lipid levels, diabetes, hypertension, obesity), total cholesterol and LDL-cholesterol in the blood Although it lowers triglycerides, it has a genetic characteristic that has the potential to increase, so it may be a cause of increasing the risk of hyperlipidemia (especially hypertriglyceridemia).

In the case of the Apo E3 gene type, which has at least one single disease among the risk factors for cerebrovascular disease (abnormal lipid level, diabetes, hypertension, obesity), it is easier to maintain a desirable blood lipid level than Apo E2 or Apo E4. has characteristics. However, since acquired risk factors can affect blood lipid levels, preventive management is required to maintain normal blood lipid levels.

The gene server 120 is a gene type (Genotype) information correlated with cerebrovascular disease, each genetic characteristic of the Apo E gene type and apo E2 (Apo E2), apo E2 as shown in Tables 1 to 9 above. It is preferable to include information about the E3 (Apo E3), Apo E4 (Apo E4) gene types, but is not limited thereto. In addition, apo E2 (Apo E2), apo E3 (Apo E3), apo E4 (Apo E4) gene type (Genotype) information that is correlated with the cerebrovascular disease if it is a known characteristic related to the cerebrovascular disease in relation to the gene type may correspond to

The service providing server 130 is based on the user's personal health record information and the user's genetic information derived from the genetic test result and the gene type information correlated with cerebrovascular disease, lifestyle and dietary management We can provide customized cerebrovascular disease management services that include The service providing server 130 may include an information collection module 132 , a lifestyle prescription module 134 , and a dietary prescription module 136 .

The information collection module 132 may store gene type information that is correlated with cerebrovascular disease matching the user's genetic information. More specifically, apo E gene including at least one of apo E2, E3, and E4 stored in the gene server 120 matched with a genetic test result including a cerebrovascular disease-related gene received from a genetic analysis institution Type information may be stored in the information collection module 132 .

The lifestyle prescription module 134 may prescribe a lifestyle adjustment program in consideration of the user's genetic specificity by using the gene type information stored in the information collection module 132 and the user's personal health record information. The lifestyle control program preferably includes at least any one of exercise, sobriety, and smoking cessation for suppressing the onset of cerebrovascular disease according to the user's gene type information. That is, in the lifestyle prescription module 134 , the user's current blood lipid level, diabetes, hypertension, and obesity are checked from the personal health record information, and the brain matched with the user's genetic information stored in the information collection module 132 . From the gene type information correlated with cardiovascular disease, it is possible to confirm the characteristics of cerebrovascular disease expected by the user. And it is possible to prescribe a lifestyle control program for exercise, sobriety, smoking cessation, etc. for suppressing the identified current or expected cerebrovascular disease. In this case, in the case of exercise, detailed exercises for suppression of the user's current or expected cerebrovascular disease (exercise amount in consideration of genetic specificity, exercise amount for each detailed exercise, etc.) may be included.

The diet prescription module 136 may prescribe a diet control program in consideration of the user's genetic specificity by using the gene type information and the user's personal health record information stored in the information collection module 132 . The diet control program preferably includes information on a diet and intake timing for suppressing cerebrovascular disease according to the user's gene type information. More specifically, the dietary prescription module 136 checks the user's current blood lipid level, diabetes, hypertension, and obesity from the personal health record information, and matches the user's genetic information stored in the information collection module 132 . From the gene type information correlated with the cerebral cardiovascular disease, it is possible to confirm the characteristics of the cerebrovascular disease expected by the user. And it is possible to prescribe a diet control program to suppress the identified current or expected cerebrovascular disease. The diet control program suppresses the expression of specific genes such as genes correlated with cerebrovascular disease matched with the user's genetic information and It may include foods to control and a functional diet to control the user's current or anticipated cerebrovascular disease. In addition, the diet control program may configure the diet control program by including information on timing of ingesting a meal or snack as well as a diet.

For example, through gene type information that is correlated with cerebrovascular disease matched to the user's genetic information stored in the information collection module 132 and the user's personal health record information, the user can determine the current risk factors (lipids) of cerebrovascular disease. level abnormality, diabetes, high blood pressure, obesity), if confirmed as Apo E2 genotype having one disease (especially, hypertriglyceridemia) may increase the risk. In this case, individual and intensive management is carried out according to the management guidelines for each single disease subject, and the focus is on lowering the risk of cerebrovascular disease.

Therefore, in relation to lifestyle prescription, the Apo E2 gene type is reported to be associated with atherosclerotic thrombosis, cardiogenic cerebral infarction, and cortical hemorrhage. As reported as 0.85 times higher after variable correction, a lifestyle control program for quitting smoking can be prescribed through the lifestyle prescription module 134 of the service providing server 130 of the customized cerebrovascular disease management system 100 of the present invention. And in the Apo E2 genotype, blood lipid concentration is most affected by physical ability, and through long-term exercise, men with Apo E2 have four times the blood HDL-cholesterol concentration than men with Apo E2 or Apo E3. When blood lipid improvement is required, a lifestyle control program that establishes a correct exercise plan through consultation with an expert can be prescribed.

Regarding dietary prescription, the Apo E2 gene type has a higher sugar intake than the Apo E2 or Apo E3 gene type, the higher the blood triglyceride concentration is, the higher the risk of dyslipidemia. Through the dietary prescription module 136 of the service providing server 130 of ( 100 ), it is possible to prescribe a diet control program paying attention to sugar intake through consultation with an expert.

For example, through gene type information that is correlated with cerebrovascular disease matched to the user's genetic information and personal health record information stored in the information collection module 132, the user can determine the current cerebrovascular disease risk factors (lipids). level abnormality, diabetes, high blood pressure, obesity) of the Apo E2 genotype having two complex diseases (especially, hypertriglyceridemia) may increase the risk. In this case, individual and intensive management is carried out according to the management guidelines for subjects with complex diseases, and the focus is on lowering the risk of developing cerebrovascular disease.

Therefore, in relation to lifestyle prescription, the Apo E2 gene type is reported to be associated with atherosclerotic thrombosis, cardiogenic cerebral infarction, and cortical hemorrhage. As reported as 0.85 times higher after variable correction, a lifestyle control program for quitting smoking can be prescribed through the lifestyle prescription module 134 of the service providing server 130 of the customized cerebrovascular disease management system 100 of the present invention. And in the Apo E2 genotype, blood lipid concentration is most affected by physical ability, and through long-term exercise, men with Apo E2 have four times the blood HDL-cholesterol concentration than men with Apo E2 or Apo E3. It is possible to increase the level, so through consultation with an expert, a lifestyle control program that regularly exercises to improve blood lipids can be prescribed.

Regarding dietary prescription, a high-fat diet is known to have a strong association with blood LDL-cholesterol levels in the Apo E2 genotype. prescribing service provider diet to develop a meal plan that can reduce the saturated fatty acid intake professional counseling through dietary regimen module 136 of the server 130, a program of the present invention personalized disease management system (100) reported. can do.

For example, through gene type information that is correlated with cerebrovascular disease matched to the user's genetic information and personal health record information stored in the information collection module 132, the user can determine the current cerebrovascular disease risk factors (lipids). level abnormality, diabetes, hypertension, obesity), if confirmed as the Apo E2 genotype with 3 or more complex diseases It has the potential to increase the risk of hyperlipidemia (especially hypertriglyceridemia). In addition, the Apo E2 gene type has been reported to be associated with atherosclerotic thrombosis, cardiogenic cerebral infarction, and cortical hemorrhage. In this case, there are several risk factors for cerebrovascular disease, and most of them can be dealt with with changes in diet and lifestyle. And, if you have cerebrovascular disease, you need to strictly follow the management of each risk factor.

Therefore, with regard to lifestyle prescription, it was reported that the risk of coronary heart disease was 1.18 times higher for smokers of this Apo E2 gene type compared to non-smokers, and 0.85 times higher after variable correction. Through the lifestyle prescription module 134 of the service providing server 130, it is possible to prescribe a lifestyle control program for quitting smoking. And in the Apo E2 genotype, blood lipid concentration is most affected by physical ability, and through long-term exercise, men with Apo E2 have four times the blood HDL-cholesterol concentration than men with Apo E2 or Apo E3. It is possible to increase the level, so a lifestyle control program that regularly exercises to improve blood lipids through consultation with a specialist can be prescribed.

Regarding dietary regimen, this Apo E2 genotype is reported to lower blood total cholesterol and LDL-cholesterol (0.60±0.14 mmol/L) through a dietary fiber-rich diet such as wheat or oat bran. Now, through the dietary prescription module 136 of the service providing server 130 of the present invention customized vascular disease management system 100, you can prescribe a diet control program that establishes a dietary fiber-rich meal plan through consultation with an expert. have.

For example, through gene type information that is correlated with cerebrovascular disease matched to the user's genetic information and personal health record information stored in the information collection module 132, the user can determine the current cerebrovascular disease risk factors (lipids). If the Apo E3 genotype is identified as having one single disease (abnormal level, diabetes, hypertension, obesity), it has a genetic trait that makes it easier to maintain desirable blood lipid levels than Apo E2 or Apo E4. However, since acquired risk factors can affect blood lipid levels, preventive management is required to maintain normal blood lipid levels. In this case, individual and intensive management is carried out according to the management guidelines for each single disease subject, and the focus is on lowering the risk of cerebrovascular disease.

Therefore, in relation to lifestyle prescription, it was reported that smokers of this Apo E3 gene type had a 2.99 times higher risk of stroke than non-smokers. A lifestyle control program for quitting smoking may be prescribed through the lifestyle prescription module 134 . In addition, it has been reported that this Apo E3 gene type can lower blood triglyceride levels in men with Apo E3 through long-term exercise. A lifestyle control program that establishes an exercise plan can be prescribed.

Regarding dietary prescription, this Apo E3 gene type has been reported to reduce total cholesterol in blood by 8.5% and increase the risk of myocardial infarction 1.49 times by consuming high levels of saturated fatty acids through nutritional counseling. Through the dietary prescription module 136 of the service providing server 130 of the system 100, it is possible to prescribe a diet control program that establishes a meal plan that can reduce saturated fatty acid intake through consultation with an expert.

For example, through gene type information that is correlated with cerebrovascular disease matched to the user's genetic information and personal health record information stored in the information collection module 132, the user can determine the current cerebrovascular disease risk factors (lipids). If the Apo E3 genotype has two complex diseases (abnormal level, diabetes, high blood pressure, obesity), it has a genetic trait that makes it easier to maintain desirable blood lipid levels than Apo E2 or Apo E4. However, since acquired risk factors can affect blood lipid levels, preventive management is required to maintain normal blood lipid levels. In this case, individual and intensive management is carried out according to the management guidelines for each complex disease subject, and the focus is on lowering the risk of developing cerebrovascular disease.

Therefore, in relation to lifestyle prescription, it was reported that the risk of stroke was 2.99 times higher for smokers of the Apo E3 gene type compared to non-smokers with the Apo E3 gene type. Through the lifestyle prescription module 134 of the server 130, it is possible to prescribe a lifestyle adjustment program for quitting smoking.

With regard to dietary prescriptions, these Apo E3 gene type of Ingestion of high levels of saturated fatty myocardial infarction risk is reported nopahjindago 1.49 times the bar, offering my invention personalized cardiovascular disease management system 100, the service server (130) Through the dietary prescription module 136, it is possible to prescribe a diet control program that establishes a meal plan that can reduce saturated fatty acid intake through consultation with an expert. In addition, as a result of ingesting whole grain powder (70g) instead of rice for breakfast for 16 weeks in coronary atherosclerosis subjects, triglycerides 12%, total cholesterol 6%, and LDL-cholesterol 9% were reduced in the case of the Apo E3 genotype. , HDL-cholesterol has been reported to increase by 9%, so a diet control program that suggests whole grain intake can be prescribed through consultation with an expert when adjusting the diet.

For example, through gene type information that is correlated with cerebrovascular disease matched to the user's genetic information and personal health record information stored in the information collection module 132, the user can determine the current cerebrovascular disease risk factors (lipids). If the Apo E3 genotype is identified as having three or more complex diseases among abnormal levels, diabetes, hypertension, obesity), it has a genetic characteristic that makes it easier to maintain a desirable blood lipid level than Apo E2 or Apo E4. In addition, there are several risk factors for cerebrovascular disease, and most of them can be dealt with with changes in diet and lifestyle. And if you have cerebrovascular disease, you need to strictly follow the management of each risk factor.

Regarding lifestyle prescription, it is known that smoking increases the oxidation of lipoproteins and increases the risk of coronary heart disease in the case of this Apo E3 genotype. In addition, it has been reported that when subjects of this Apo E3 gene type smoke, the risk of coronary heart disease is 1.68 times higher than that of nonsmokers, and 1.47 times higher after variable adjustment. It has been reported that the risk of stroke was 2.99 times higher than that of non-smokers. Accordingly, a lifestyle control program for quitting smoking can be prescribed through the lifestyle prescription module 134 of the service providing server 130 of the customized cerebrovascular disease management system 100 of the present invention. And this Apo E3 genotype has been reported to decrease blood triglycerides by 12%, slightly decrease LDL-cholesterol, and _{increase V O2} max by 5% through exercise, which results in aerobic activity through exercise. capacity), so a lifestyle control program that recommends exercise according to the management guidelines can be prescribed.

Regarding dietary prescription, this Apo E3 gene type has been reported to reduce total blood cholesterol by 6.6±2.1% through a dietary fiber-rich diet (>5.7 g/MJ). ) through the dietary prescription module 136 of the service providing server 130 may prescribe a dietary control program to establish a dietary fiber-rich meal plan through consultation with an expert.

For example, through gene type information that is correlated with cerebrovascular disease matched to the user's genetic information and personal health record information stored in the information collection module 132, the user can determine the current cerebrovascular disease risk factors (lipids). If the Apo E4 genotype is identified as having one single disease of abnormal level, diabetes, high blood pressure, and obesity), it has a genetic characteristic that has the potential to increase total cholesterol, LDL-cholesterol and triglycerides in the blood, resulting in hyperlipidemia (especially , hypercholesterolemia) may increase the risk. In this case, individual and intensive management is carried out according to the management guidelines for each single disease subject, and the focus is on lowering the risk of cerebrovascular disease.

Regarding lifestyle prescription, this Apo E4 gene type is reported to be associated with atherosclerotic thrombosis, cortical hemorrhage, and subarachnoid hemorrhage, and Apo E4 is known to be a genetic cause of hyperlipidemia. Therefore, the lifestyle control program for smoking cessation and exercise can be prescribed through the lifestyle prescription module 134 of the service providing server 130 of the customized cerebrovascular disease management system 100 of the present invention.

Regarding dietary prescription, it is thought that these Apo E4 genotype dyslipidemic subjects can significantly lower blood total cholesterol through nutritional counseling. It is known that the total cholesterol in the blood decreased by 15.6%. In addition, it has been reported that when subjects of the Apo E4 gene type follow a low-fat diet, the effect of reducing blood cholesterol and LDL-cholesterol is greater than that of subjects of other gene types. And the Apo E4 gene type dyslipidemia subjects reported a 14.1% reduction in total cholesterol with the NCEP diet, the dietary prescription module 136 of the service providing server 130 of the cerebrovascular disease management system 100 customized according to the present invention. ) through which you can prescribe a diet control program that establishes a meal plan to actively follow the NECP diet. In addition, in the case of subjects with hyperlipidemia of the Apo E4 gene type, a dietary control program that restricts caloric intake and dietary fat, particularly saturated fatty acid and cholesterol, can be prescribed to maintain normal body weight when dieting.

For example, through gene type information that is correlated with cerebrovascular disease matched to the user's genetic information and personal health record information stored in the information collection module 132, the user can determine the current cerebrovascular disease risk factors (lipids). If the Apo E4 genotype is identified as having two complex diseases among the abnormal level, diabetes, high blood pressure, and obesity), blood total cholesterol, LDL-cholesterol, and triglycerides have a genetic characteristic that has the potential to increase, so hyperlipidemia (especially , hypercholesterolemia) may increase the risk. In this case, individual and intensive management is carried out according to the management guidelines for subjects with complex diseases, and the focus is on lowering the risk of developing cerebrovascular disease.

Regarding lifestyle prescription, this Apo E4 genotype is associated with atherosclerotic thrombosis, cardiogenic cerebral infarction, and cortical hemorrhage. has been reported Therefore, the lifestyle control program for quitting smoking can be prescribed through the lifestyle prescription module 134 of the service providing server 130 of the customized cerebrovascular disease management system 100 of the present invention. And it was reported that a drinker of the Apo E4 gene type has a 1.5 times higher risk of carotid atherosclerosis than a non-drinker of the same gene type. can do. In addition, the frequency of Apo E4 is reported to be significantly higher when there is a history of ischemic stroke than when there is no history. If there is a family history, the risk of developing cerebrovascular disease through the lifestyle prescription module 134 of the service providing server 130 A lifestyle adjustment program may be prescribed to lower the

Regarding dietary regimen, this Apo E3 genotype can prescribe a dietary control program that establishes a meal plan that reduces total fat and saturated fatty acid intake and reduces body fat retention to reduce blood cholesterol. In particular, in the case of this Apo E4 gene type, it is necessary to be careful with excessive intake of calories and dietary fat to prevent an increase in total cholesterol and LDL-cholesterol in the blood. A conditioning program may be prescribed.

For example, through gene type information that is correlated with cerebrovascular disease matched to the user's genetic information and personal health record information stored in the information collection module 132, the user can determine the current cerebrovascular disease risk factors (lipids). If it is identified as the Apo E4 gene type with 3 or more complex diseases among abnormal levels, diabetes, high blood pressure, obesity), it has a genetic characteristic that has the potential to increase total cholesterol, LDL-cholesterol and triglycerides in the blood, so hyperlipidemia ( In particular, hypercholesterolemia) may increase the risk. As a result of meta-analysis of 48 research papers on the relationship between Apo E gene polymorphisms and coronary heart disease, it was reported that subjects with this Apo E4 genotype had a 1.42 times higher risk of coronary heart disease than subjects with the Apo E3 genotype. Therefore, in this case, focus on lowering the risk of cerebrovascular disease and practice lifestyle improvement.

There are several risk factors for cerebrovascular disease, most of which can be dealt with with diet and lifestyle changes. Therefore, in the absence of cerebrovascular disease, it is necessary to emphasize the active treatment of risk factors for cerebrovascular disease.

With regard to lifestyle prescription, it was reported that when these Apo E4 genotype subjects smoked, the risk of coronary heart disease was 2.79 times higher after variable adjustment than non-smokers. Service of the present invention customized cerebrovascular disease management system 100 Through the lifestyle prescription module 134 of the providing server 130, it is possible to prescribe a lifestyle adjustment program for quitting smoking. In addition, since women of the Apo E4 gene type have a earlier menopause age than other gene types, management of cardiovascular diseases and chronic diseases due to menopause through the lifestyle prescription module 134 of the service provision server 130 of the system 100 A lifestyle control program that pays attention to

Regarding dietary prescription, this Apo E3 genotype has been reported that the Apo E4 genotype increases the LDL-cholesterol concentration as the intake of saturated fatty acids increases and increases the risk of coronary artery disease. can be prescribed. Also, according to the Apo E4 gene research results, it is known that blood triglycerides and total cholesterol significantly decrease through the intake of unsaturated fatty acids, so a diet control program that recommends a diet rich in unsaturated fatty acids can be prescribed.

The service providing server 130 may further include a diet management module 138 in addition to the information collection module 132 , the lifestyle prescription module 134 , and the diet prescription module 136 . The diet management module 138 may diagnose the eating habits collected from the user and track the nutritional management status according to the diet control program prescribed by the diet prescription module 136 . That is, the diet management module 138 may collect and diagnose eating habits information through the user device, and collect eating habits information from the user for a predetermined period, such as a week, to enable an accurate diagnosis of the current eating habits. . In addition, the diet management module 138, by collecting and analyzing the nutritional information consumed through the user device, can track and manage the nutritional management status whether the prescribed diet control program is well followed, and adjust the diet from the current eating habits It can be judged whether or not improvement is made through the program.

The user terminal 140 transmits a request to provide a customized cerebrovascular disease management service to the service providing server 130, or the user can check the customized cerebrovascular disease management service provided by the service providing server 130. can be displayed as More specifically, when receiving a request for providing a customized cerebrovascular disease management service including lifestyle and dietary management from the user terminal 140 , the service providing server 130 receives the user's personal health record information from the information collection module And after storing the gene type information correlated with cerebrovascular disease matched to the user's genetic information, the stored gene type information is used to prescribe a lifestyle control program and a diet control program in consideration of the user's genetic specificity. . The prescribed programs can be checked through the user terminal 140 . In addition, the user terminal 140 is a service providing server 130 that provides the customized cerebrovascular disease management service, or is provided with a program for receiving the customized cerebrovascular disease management service from the service providing server 130 . can

The user can use the customized cerebrovascular disease management service based on genetic information analysis provided by the service providing server 130 through the user device, and install an application for using the customized cerebrovascular disease management service to provide a lifestyle adjustment program and diet You can check the control program. Here, the user device may include a user's smartphone, tablet PC, and the like, and may include various wearable devices such as a smart watch and smart glasses. However, the user device is not limited to the specific shape or location of the terminal 140 as long as it can use the customized cerebrovascular disease management service by transmitting and receiving various types of information to and from the service providing server 130 .

Genetic information analysis-based customized cerebrovascular disease management method according to another embodiment of the present invention comprises the steps of: (a) obtaining the user's personal health record information, the user's genetic information derived from the genetic test result; (b) matching the user's genetic information derived from the genetic test result and the gene type information correlated with cerebrovascular disease; (c) Customized cerebrovascular disease management service including lifestyle and diet management in consideration of the user's genetic specificity using the user's personal health record information and the matched gene type information correlated with the cerebrovascular disease comprising the step of providing

The user's personal health record information preferably includes information on blood lipid levels, diabetes, high blood pressure, and obesity, but is not limited thereto. In addition, body information such as the user's weight and height may be included.

The user's genetic information derived from the user's genetic test result is a genetic test result of a genetic analysis specialized institution, and preferably includes cardiovascular-related genes, cerebrovascular-related genes, diabetes-related genes, metabolic disease-related genetic test results, etc. However, the present invention is not limited thereto.

The gene type information correlated with the cerebrovascular disease may be apo E genotype information. The apo E genotype correlated with the cerebrovascular disease preferably includes at least one of apo E2 (Apo E2), apo E3 (Apo E3), and apo E4 (Apo E4).

The customized cerebrovascular disease management service of step (c) may include a lifestyle control program and a diet control program in consideration of the genetic specificity of the user using the gene type information correlated with the matched cerebrovascular disease. can

The lifestyle control program may include at least one of exercise, sobriety, and smoking cessation for suppressing cerebrovascular disease according to gene type information correlated with the matched cerebrovascular disease. In this case, in the case of exercise, detailed exercises for suppression of the user's current or expected cerebrovascular disease (exercise amount in consideration of genetic specificity, exercise amount for each detailed exercise, etc.) may be included.

The diet control program may include diet and intake timing information for suppressing cerebrovascular disease according to the matched gene type information correlated with the cerebrovascular disease. The diet control program may include a food that regulates the expression of a specific gene, such as a gene correlated with cerebrovascular disease, matched with the user's genetic information, and a functional diet for suppressing the user's current or expected cerebrovascular disease. can In addition, the diet control program may configure the diet control program by including information on timing of ingesting a meal or snack as well as a diet.

The customized cerebrovascular disease management service of step (C) may further include a diet management program in addition to the lifestyle control program and the diet control program. The diet management program may diagnose the eating habits collected from the user and track the nutritional management status according to the diet control program. That is, the diet management program may collect and diagnose eating habits information through the user device, and may enable accurate diagnosis of the current eating habits by collecting eating habits information from the user for a predetermined period such as a week. In addition, the diet management program, by collecting and analyzing the nutritional information consumed through the user device, can track and manage the nutritional management status of whether the prescribed diet control program is well followed, and through the diet control program from the current eating habits. improvement can be determined.

The genetic information analysis-based customized cerebrovascular disease management system 100 according to the present invention described above is not limited to the above-described embodiment, and the embodiments are only for illustrating the present invention, and the scope of the present invention is not limited to these embodiments. It will be apparent to those of ordinary skill in the art that the examples are not to be construed as limited.

Claims (15)

a communication server for receiving the user's personal health record information and the user's genetic information derived from the genetic test result;
A gene server that stores information on a gene type (Genotype) correlated with cerebrovascular disease;
Based on the user's personal health record information, the user's genetic information derived from the genetic test result, and the genotype information correlated with cerebrovascular disease, a customized cerebrovascular disease management service including lifestyle and dietary management is provided. a service providing server to provide;
A user terminal for transmitting a request to provide a customized cerebrovascular disease management service to the service providing server, or displaying a customized cerebrovascular disease management service provided by the service providing server so that the user can check,
The personal health record information of the user received from the communication server includes information on blood lipid levels, diabetes, hypertension, and obesity,
The gene type information stored in the gene server is apo E genotype information, which is apo E3 information,
Users of the Apo E3 type can reduce the risk of stroke by quitting smoking, reduce the risk of myocardial infarction, triglycerides, total cholesterol, and LDL-cholesterol through diet control, increase HDL-cholesterol, and exercise can reduce blood triglycerides,
The service providing server includes: an information collection module for storing Apo E3 as gene type information correlated with cerebrovascular disease matched to the user's genetic information derived from the genetic test result;
a lifestyle prescription module for prescribing a lifestyle control program in consideration of the user's genetic specificity using the Apo E3 information stored in the information collection module and the user's personal health record information;
A dietary prescription module for prescribing a diet control program in consideration of the user's genetic specificity using the Apo E3 information stored in the information collection module and the user's personal health record information,
In the lifestyle prescription module, the user's current blood lipid level, diabetes, hypertension, and obesity are checked from the personal health record information, and the characteristics of cerebrovascular disease expected to the user can be confirmed from the apo E3 information stored in the information collection module. And, it is possible to prescribe a lifestyle control program for exercise and smoking cessation to suppress the identified current or expected cerebrovascular disease,
In the dietary prescription module, the user's current blood lipid level, diabetes, high blood pressure, and obesity are checked from the personal health record information, and the characteristics of cerebrovascular disease expected to the user are confirmed from the apo E3 information stored in the information collection module. can, and can prescribe a diet control program to suppress the identified current or expected cerebrovascular disease,
The lifestyle control program includes at least one of exercise and smoking cessation for suppressing cerebrovascular disease according to the apo E3 information,
The diet control program includes diet and intake timing information for suppressing cerebrovascular disease according to the apo E3 information,
The user terminal can be a service providing server that provides a customized cerebrovascular disease management service, or has a program for receiving a customized cerebrovascular disease management service from the service providing server. Cerebrovascular disease management system.
delete delete delete delete delete delete delete (a) obtaining the user's personal health record information and the user's genetic information derived from the genetic test result in the communication server;
(b) matching the user's genetic information derived from the genetic test result in the gene server with the gene type information correlated with cerebrovascular disease;
(c) lifestyle and diet management in consideration of the user's genetic specificity by using the user's personal health record information and the matched gene type information correlated with the cerebrovascular disease in the service providing server,
(d) transmitting a request for providing a customized cerebrovascular disease management service from the user terminal to the service providing server, or displaying the customized cerebrovascular disease management service provided by the service providing server so that the user can check; including,
The personal health record information of the user received from the communication server includes information on blood lipid levels, diabetes, hypertension, and obesity,
The gene type information stored in the gene server is apo E genotype information, which is apo E3 information,
Users of the Apo E3 type can reduce the risk of stroke by quitting smoking, reduce the risk of myocardial infarction, triglycerides, total cholesterol, and LDL-cholesterol through diet control, increase HDL-cholesterol, and exercise can reduce blood triglycerides,
The service providing server includes: an information collection module for storing Apo E3 as gene type information correlated with cerebrovascular disease matched to the user's genetic information derived from the genetic test result;
a lifestyle prescription module for prescribing a diet control program in consideration of the user's genetic specificity using the Apo E3 information stored in the information collection module and the user's personal health record information;
A dietary prescription module for prescribing a diet control program in consideration of the user's genetic specificity using the Apo E3 information stored in the information collection module and the user's personal health record information,
In the lifestyle prescription module, the user's current blood lipid level, diabetes, hypertension, and obesity are checked from the personal health record information, and the characteristics of cerebrovascular disease expected to the user are confirmed from the apo E3 information stored in the information collection module. Can, and can prescribe a lifestyle control program for exercise smoking cessation to suppress the identified current or expected cerebrovascular disease,
In the dietary prescription module, the user's current blood lipid level, diabetes, high blood pressure, and obesity are checked from the personal health record information, and the characteristics of cerebrovascular disease expected to the user are confirmed from the apo E3 information stored in the information collection module. can, and can prescribe a diet control program to suppress the identified current or expected cerebrovascular disease,
The lifestyle control program includes at least one of exercise and smoking cessation for suppressing cerebrovascular disease according to the user's Apo E3 information,
The diet control program includes diet and intake timing information for suppressing cerebrovascular disease according to the apo E3 information,
The user terminal can be a service providing server that provides a customized cerebrovascular disease management service, or has a program for receiving a customized cerebrovascular disease management service from the service providing server. How to manage cerebrovascular disease. delete delete delete delete delete delete

Images